Marcia Brose, MD, PhD, discusses the importance of genomic testing in patients with thyroid cancer.
Marcia Brose, MD, PhD, director of the Center for Rare Cancers and Personalized Therapy, director of the Thyroid Cancer Therapeutics Program, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, and associate professor of Medicine at Penn Medicine, discusses the importance of genomic testing in patients with thyroid cancer.
There are so many targeted therapies now for thyroid cancer that it is important to know the genetic and genomic landscape for patients prior to starting even systemic treatment, says Brose. There are 2 reasons for this.
The first reason is about treatment planning. Physicians may want to sequence the different therapies available based on what is available for the patient, Brose says. The second reason is that all approved agents are not the same when it comes to the tolerability of the drug. If a patient has access to a more tolerable agent due to a genetic marker in the tumor, physicians want to know that information because they can start the patient on a different treatment and not deal with quite as high a side effect profile.
<< View more resources and information regarding thyroid cancer
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More